Innovative Diagnostic Platform Cleveland Diagnostics' IsoClear™ platform leverages protein structure analysis to develop novel diagnostic tests, demonstrating a strong focus on advanced biotech solutions which could appeal to healthcare providers seeking cutting-edge diagnostic tools.
Strong Market Validation The company has achieved favorable Medicare coverage for its IsoPSA prostate cancer test and launched multiple studies, indicating regulatory and scientific validation that can facilitate further adoption among medical institutions.
Recent Funding Success With a recent $75 million financing round and previous Series D funding of $17.4 million, Cleveland Diagnostics has substantial financial resources to expand its product lines and accelerate market penetration.
Expanding Leadership The appointment of a new board member, Dara Grantham Wright, along with key medical hires such as Chief Medical Officer Dr. Mark Stovsky, reflects strategic leadership growth, which can enhance credibility and foster new partnerships.
Focus on Cancer Detection The company's launch of prostate cancer awareness campaigns and IsoPSA studies indicates a targeted effort in oncology diagnostics, creating opportunities to collaborate with medical centers and organizations focusing on cancer screening and early detection.
Cleveland Diagnostics, Inc. uses 8 technology products and services including GDPR, Drupal, Google Fonts API, and more. Explore Cleveland Diagnostics, Inc.'s tech stack below.
| Cleveland Diagnostics, Inc. Email Formats | Percentage |
| First.Last@cleveland-diagnostics.com | 97% |
| Last@cleveland-diagnostics.com | 3% |
| First.Last@clevelanddx.com | 92% |
| Last@clevelanddx.com | 8% |
Biotechnology ResearchOhio, United States51-200 Employees
Cleveland Diagnostics has unlocked the diagnostic power of protein structure with its revolutionary IsoClear™ platform to develop novel diagnostics based on protein structure-based assessment.
Company Overview
Media & News
Funding & FinancialsCleveland Diagnostics, Inc. has raised a total of $75M of funding over 8 rounds. Their latest funding round was raised on Jan 17, 2024 in the amount of $75M.
Cleveland Diagnostics, Inc.'s revenue is estimated to be in the range of $25M$50M
Funding & FinancialsCleveland Diagnostics, Inc. has raised a total of $75M of funding over 8 rounds. Their latest funding round was raised on Jan 17, 2024 in the amount of $75M.
Cleveland Diagnostics, Inc.'s revenue is estimated to be in the range of $25M$50M
1-888-653-2347 
support@leadiq.com